GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (NAS:CRBP) » Definitions » ROC (Joel Greenblatt) %

CRBP (Corbus Pharmaceuticals Holdings) ROC (Joel Greenblatt) % : -1,735.17% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Corbus Pharmaceuticals Holdings ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Corbus Pharmaceuticals Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -1,735.17%.

The historical rank and industry rank for Corbus Pharmaceuticals Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:

CRBP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9948.31   Med: -1978.79   Max: -557.36
Current: -1198.04

During the past 11 years, Corbus Pharmaceuticals Holdings's highest ROC (Joel Greenblatt) % was -557.36%. The lowest was -9948.31%. And the median was -1978.79%.

CRBP's ROC (Joel Greenblatt) % is ranked worse than
70.57% of 1410 companies
in the Biotechnology industry
Industry Median: -307.695 vs CRBP: -1198.04

Corbus Pharmaceuticals Holdings's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 20.50% per year.


Corbus Pharmaceuticals Holdings ROC (Joel Greenblatt) % Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings ROC (Joel Greenblatt) % Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,133.23 -1,214.80 -686.22 -557.36 -945.61

Corbus Pharmaceuticals Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -792.49 -1,083.39 -999.92 -1,076.30 -1,735.17

Competitive Comparison of Corbus Pharmaceuticals Holdings's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's ROC (Joel Greenblatt) % falls into.



Corbus Pharmaceuticals Holdings ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.286) - (9.343 + 0 + 2.297)
=-10.354

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.528) - (8.24 + 0 + 1.823)
=-8.535

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Corbus Pharmaceuticals Holdings for the quarter that ended in Sep. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-53.608/( ( (3.283 + max(-10.354, 0)) + (2.896 + max(-8.535, 0)) )/ 2 )
=-53.608/( ( 3.283 + 2.896 )/ 2 )
=-53.608/3.0895
=-1,735.17 %

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corbus Pharmaceuticals Holdings  (NAS:CRBP) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Corbus Pharmaceuticals Holdings ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Corbus Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Executives
Yuval Cohen director, officer: Chief Executive Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Sean F. Moran officer: Chief Financial Officer 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Yong Ben director 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Anne Altmeyer director 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Craig Stuart Millian officer: Chief Commercial Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachael Louise Brake officer: Chief Scientific Officer 21 MANCHESTER PLACE, NATICK MA 01760
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Peter Salzmann director 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Barbara White officer: Chief Medical Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Paul Discordia officer: Chief Operating Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David P Hochman director 15 WESTON HILL RD., RIVERSIDE CT 06878
John Kenneth Jenkins director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Avery W Catlin director 241 CENTRAL STREET, HINGHAM MA 02043